SCHEMBL7220875

SCHEMBL7220875

[CH2]c1coc(C=NO)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7220874 1.00
SCHEMBL24325670 0.74
SCHEMBL7220878 0.74
SCHEMBL321717 0.61 SMN1; SMN2 (0.59)
SCHEMBL3079633 0.59
SCHEMBL5898764 0.59
SCHEMBL29444829 0.59 SMN1; SMN2 (0.57)
SCHEMBL28565605 0.59 SMN1; SMN2 (0.57)
SCHEMBL28556984 0.59 SMN1; SMN2 (0.57)
SCHEMBL29444862 0.59 SMN1; SMN2 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6503898-B1 Administering 4,7-dibenzyl-5,6-dihydroxy-N,N*-di(m-aminobenzyl)--1,3-diazepin-2-one or salt to treat human immunodeficiency virus infection BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed